Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $580000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 37.83% year-over-year to $580000.0; the TTM value through Dec 2025 reached $580000.0, down 37.83%, while the annual FY2025 figure was $580000.0, 37.83% down from the prior year.
  • Other Non-Current Liabilities hit $580000.0 in Q4 2025 for Sangamo Therapeutics, down from $977000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $7.6 million in Q3 2021 and bottomed at $580000.0 in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $2.1 million, with a median of $1.2 million recorded in 2023.
  • Year-over-year, Other Non-Current Liabilities increased 22.93% in 2021 and then plummeted 82.9% in 2022.
  • Sangamo Therapeutics' Other Non-Current Liabilities stood at $1.2 million in 2021, then dropped by 0.82% to $1.2 million in 2022, then dropped by 1.66% to $1.2 million in 2023, then decreased by 21.4% to $933000.0 in 2024, then tumbled by 37.83% to $580000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $580000.0, $977000.0, and $962000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.